Brief: Zentalis Pharmaceuticals Announces 400Mg Qd 52 Azenosertib Monotherapy As The Pivotal Study Dose In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
09/04/2026 13:42
April 9 (Reuters) - Zentalis Pharmaceuticals Inc ZNTL.O: ZENTALIS PHARMACEUTICALS ANNOUNCES 400MG QD 5:2 AZENOSERTIB MONOTHERAPY AS THE PIVOTAL STUDY DOSE IN CYCLIN E1-POSITIVE PLATINUM-RESISTANT OVARIAN CANCER ZENTALIS PHARMACEUTICALS INC - DENALI PART 2 TOPLINE READOUT EXPECTED BY YEAR-END 2026 ZENTALIS PHARMACEUTICALS INC - DENALI PART 2C COHORT ENROLLMENT PLANNED FOR Q2 2026 Source text: ID:nGNXc0S9YJ Further company coverage: ZNTL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer